Thermo Fisher Scientific's Strategic Moves and Financial Performance in 2026

Thermo Fisher Scientific’s Strategic Moves and Financial Performance in 2026

Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has recently undertaken significant strategic initiatives, including divestitures and acquisitions, alongside reporting robust financial results for the second quarter of 2026.

Divestiture of Microbiology Business

On April 27, 2026, Thermo Fisher announced a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. This transaction includes cash and a $50 million seller note. The microbiology division, which generated $645 million in revenue in 2025, specializes in antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical, and food safety applications. Marc N. Casper, Chairman and CEO of Thermo Fisher, stated that this move reflects the company’s active management strategy and provides additional capital to create shareholder value. The deal is expected to close in the second half of 2026 and is anticipated to be dilutive to adjusted earnings per share by $0.15 in the first full year post-closure.

Acquisition of Sanofi’s Ridgefield Facility

In September 2025, Thermo Fisher completed the acquisition of Sanofi’s sterile fill-finish and packaging site in Ridgefield, New Jersey. This acquisition aims to expand U.S. drug product manufacturing capacity to meet the growing demand from pharmaceutical and biotech customers. Under the agreement, Thermo Fisher will continue manufacturing a portfolio of therapies for Sanofi at the Ridgefield site while also utilizing the facility to serve other clients.

Second Quarter 2026 Financial Performance

Thermo Fisher reported strong financial results for the second quarter of 2026, with revenue growing by 10% to $11.99 billion. GAAP diluted earnings per share (EPS) increased by 9% to $4.68, while adjusted EPS grew by 13% to $6.03. Marc N. Casper attributed this performance to the company’s proven growth strategy, excellent execution, and the strength of the PPI Business System. He also noted that customer activity across end markets continued to strengthen, leading to continued market share gains.

Market Performance

As of July 24, 2026, Thermo Fisher’s stock (TMO) was trading at $568.26, reflecting a slight decrease of 0.31% from the previous close. The stock’s intraday high reached $574.00, with a low of $556.30. The company’s market capitalization stands at approximately $211.96 billion, with a price-to-earnings (PE) ratio of 31.24 and earnings per share (EPS) of $18.19.

Conclusion

Thermo Fisher Scientific’s recent strategic decisions, including the divestiture of its microbiology business and the acquisition of Sanofi’s Ridgefield facility, demonstrate the company’s commitment to optimizing its portfolio and expanding its capabilities. These moves, coupled with strong financial performance in the second quarter of 2026, position Thermo Fisher for continued growth and value creation for shareholders.